237 related articles for article (PubMed ID: 37106270)
41. Exposure-Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer Patients.
Groenland SL; Geel DR; Janssen JM; de Vries N; Rosing H; Beijnen JH; Burgers JA; Smit EF; Huitema ADR; Steeghs N
Clin Pharmacol Ther; 2021 Feb; 109(2):394-402. PubMed ID: 32686074
[TBL] [Abstract][Full Text] [Related]
42. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS).
Huang J; Zhao Y; Cao Y; Zhang Q; Ran D; Li J; Luo L; Qiu F; Meng L
Int J Clin Pharm; 2022 Aug; 44(4):993-1003. PubMed ID: 35776375
[TBL] [Abstract][Full Text] [Related]
43. Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program.
Lin HM; Pan X; Hou P; Allen S; Baumann P; Hochmair MJ
Future Oncol; 2020 May; 16(15):1031-1041. PubMed ID: 32338548
[No Abstract] [Full Text] [Related]
44. Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L.
Reckamp KL; Lin HM; Cranmer H; Wu Y; Zhang P; Kay S; Walton LJ; Shen J; Popat S; Camidge DR
Curr Med Res Opin; 2022 Sep; 38(9):1587-1593. PubMed ID: 35815801
[TBL] [Abstract][Full Text] [Related]
45. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Mok T; Camidge DR; Gadgeel SM; Rosell R; Dziadziuszko R; Kim DW; Pérol M; Ou SI; Ahn JS; Shaw AT; Bordogna W; Smoljanović V; Hilton M; Ruf T; Noé J; Peters S
Ann Oncol; 2020 Aug; 31(8):1056-1064. PubMed ID: 32418886
[TBL] [Abstract][Full Text] [Related]
46. Update of Diagnosis and Targeted Therapy for ALK
Wang QA; Chen HW; Wu RC; Wu CE
Curr Treat Options Oncol; 2023 Dec; 24(12):1683-1702. PubMed ID: 37938503
[TBL] [Abstract][Full Text] [Related]
47. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
[TBL] [Abstract][Full Text] [Related]
48. ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis.
Cirne F; Zhou S; Kappel C; El-Kadi A; Barron CC; Ellis PM; Sanger S; Leong DP
Lung Cancer; 2021 Nov; 161():9-17. PubMed ID: 34492553
[TBL] [Abstract][Full Text] [Related]
49. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
[TBL] [Abstract][Full Text] [Related]
50. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
Camidge DR; Kim HR; Ahn MJ; Yang JC; Han JY; Lee JS; Hochmair MJ; Li JY; Chang GC; Lee KH; Gridelli C; Delmonte A; Garcia Campelo R; Kim DW; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger SN; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S
N Engl J Med; 2018 Nov; 379(21):2027-2039. PubMed ID: 30280657
[TBL] [Abstract][Full Text] [Related]
51. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
52. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
[TBL] [Abstract][Full Text] [Related]
53. Indirect comparisons of brigatinib and alectinib for front-line
Reckamp KL; Lin HM; Cranmer H; Wu Y; Zhang P; Walton LJ; Kay S; Cichewicz A; Neupane B; Fahrbach K; Popat S; Camidge DR
Future Oncol; 2022 Jun; 18(20):2499-2510. PubMed ID: 35608148
[TBL] [Abstract][Full Text] [Related]
54. Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States.
Jahanzeb M; Lin HM; Wu Y; Zhang P; Gorritz M; McGuiness CB; Huang WT; Sun K; Chen CC; Camidge DR
Oncologist; 2022 Sep; 27(9):790-798. PubMed ID: 35781589
[TBL] [Abstract][Full Text] [Related]
55. ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences.
Cicin I; Martin C; Haddad CK; Kim SW; Smolin A; Abdillah A; Yang X
Crit Rev Oncol Hematol; 2022 Dec; 180():103847. PubMed ID: 36257531
[TBL] [Abstract][Full Text] [Related]
56. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
Roskoski R
Pharmacol Res; 2017 Mar; 117():343-356. PubMed ID: 28077299
[TBL] [Abstract][Full Text] [Related]
57. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
58. Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
Yanagitani N; Uchibori K; Koike S; Tsukahara M; Kitazono S; Yoshizawa T; Horiike A; Ohyanagi F; Tambo Y; Nishikawa S; Fujita N; Katayama R; Nishio M
Cancer Sci; 2020 Mar; 111(3):932-939. PubMed ID: 31961053
[TBL] [Abstract][Full Text] [Related]
59. An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer.
Hamilton G; Hochmair MJ
Expert Opin Pharmacother; 2019 Sep; 20(13):1551-1561. PubMed ID: 31328968
[No Abstract] [Full Text] [Related]
60. Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China.
Zou Z; Hao X; Zhang C; Li H; Dong G; Peng Y; Ma K; Guo Y; Shan L; Zhang Y; Liang L; Gu Y; Xing P; Li J
Thorac Cancer; 2022 Jan; 13(1):107-116. PubMed ID: 34851035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
